Skip to main content

NVCR

Stock

NVCR

Stock
Health Care
Medical Devices

Performance overview

NVCR Price
Price Chart

Forward-looking statistics

Beta
1.92
Risk
84.99%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Company info

SectorHealth Care
IndustryMedical Devices
Employees1K
Market cap$2.3B

Fundamentals

Enterprise value$1.8B
Revenue$621.7M
Revenue per employee
Profit margin-26.41%
Debt to equity192.49

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.51
Dividend per share
Revenue per share$5.73
Avg trading volume (30 day)$28M
Avg trading volume (10 day)$27M
Put-call ratio

Macro factor sensitivity

Growth+1.0
Credit+6.5
Liquidity-3.3
Inflation-3.0
Commodities-0.5
Interest Rates-2.1

Valuation

Dividend yield0.00%
PEG Ratio-11.81
Price to sales3.18
P/E Ratio-11.81
Enterprise Value to Revenue2.82
Price to book5.45

Upcoming events

Next earnings dayMay 2, 2024
Next dividend day
Ex. dividend day

News

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research (June 30, 2025)
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Zai Lab Limited ZLAB and NovoCure Limited NVCR revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer.

Benzinga (June 2, 2025)
Biotech stocks: Which drugmakers are worth a buy?

While the pharma space has seen growing excitement over weight-loss drugs from Eli Lilly (LLY) and Novo Nordisk's (NVO) latest earnings, investors are increasingly curious over the types of innovation biotech stocks could offer. But with so many names and new research coming out every day, it can be difficult to find where to start.

Yahoo Finance (August 12, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free